

EXPERT PERSPECTIVES: THE NEXT ERA IN THE MANAGEMENT OF METASTATIC COLORECTAL CANCER

Reference List

Andre T, Elez E, Van Cutsem E, et al: Nivolumab plus ipilimumab vs chemotherapy as first-line treatment for microsatellite instability–high/mismatch repair–deficient metastatic colorectal cancer: First results of the CheckMate 8HW study. *J Clin Oncol*. 2024;42(3 Suppl):LBA768. doi:10.1200/JCO.2024.42.3_suppl.LBA768

André T, Louvet C, Maindrault-Goebel F, et al. CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. *Eur J Cancer*. 1999;35(9):1343- 1347. doi:10.1016/s0959-8049(99)00150-1

Bokemeyer C, Cutsem EV, Rougier P, et al. Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trials. *Eur J Cancer*. 2012;48:1466-1475. doi:10.1016/j.ejca.2012.02.057

Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. *J Clin Oncol*. 2009;27(5):663-671. doi:10.1200/JCO.2008.20.8397

Bourdais R, Rousseau B, Pujals A, et al. Polymerase proofreading domain mutations: New opportunities for immunotherapy in hypermutated colorectal cancer beyond MMR deficiency. *Crit Rev Oncol Hematol*. 2017;113:242-248. doi:10.1016/j.critrevonc.2017.03.027

Cheeseman SL, Joel SP, Chester JD, et al. A ‘modified de Gramont’ regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer. *Br J Cancer*. 2002;87(4):393-399. doi:10.1038/sj.bjc.6600467

Cunningham JM, Christensen ER, Tester DJ, et al. Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability. *Cancer Res*. 1998;58(15):3455-3460. PMID: 9699680

Dasari A, Lonardi S, Garcia-Carbonero R, et al. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study. *Lancet*. 2023;402(10395):41-53. doi:10.1016/S0140-6736(23)00772-9

Dekker E, Tanis PJ, Vleugels JLA, Kasi PM, Wallace MB. Colorectal cancer. *Lancet*. 2019;394 :1467–1480. doi:10.1016/S0140-6736(19)32319-0

Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. *J Clin Oncol*. 2010;28(31):4697-4705. doi:10.1200/JCO.2009.27.4860

Emmanouilides C, Sfakiotaki G, Androulakis N, et al. Front-line bevacizumab in combination with oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study. *BMC Cancer*. 2007;7:91. doi:10.1186/1471-2407-7-91

EXPERT PERSPECTIVES: THE NEXT ERA IN THE MANAGEMENT OF METASTATIC COLORECTAL CANCER

Forgo E, Gomez AJ, Steiner D, et al. Morphological, immunophenotypical and molecular features of hypermutation in colorectal carcinomas with mutations in DNA polymerase epsilon (*POLE*). *Histopathology*. 2020;76(3):366-374. doi:10.1111/his.13984

Gatalica Z, Xiu J, Swensen J, Vranic S. Molecular characterization of cancers with NTRK gene fusions. *Mod Pathol*. 2018;32(1):147-153. doi:10.1038/s41379-018-0118-3

Grothey A, Cutsem EV, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. *The Lancet*. 2013;381(9863):303-312. doi:10.1016/s0140-6736(12)61900-x

Halvarsson B, Anderson H, Domanska K, Lindmark G, Nilbert M. Clinicopathologic factors identify sporadic mismatch repair-defective colon cancers. *Am J Clin Pathol*. 2008;129(2):238-244. doi:10.1309/OPP5GDRTXUDVKAWJ

Hanna DL, Lenz HJ. How we treat left-sided vs right-sided colon cancer. *Clin Adv Hematol Oncol*. 2020;18(5):253–257. PMID: 32628652

Heydt C, Wölwer CB, Velazquez Camacho O, et al. Detection of gene fusions using targeted next-generation sequencing: a comparative evaluation. *BMC Med Genomics*. 2021;14:62. doi:10.1186/s12920-021-00909-y

Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics review, 1975-2014. Bethesda, MD: National Cancer Institute (2017). Available at: https://seer.cancer.gov/csr/1975_2014/. Based on November 2016 SEER data submission, posted to the SEER web site.

Inada R, Takeshi Nagasaka, Shimokawa M, et al. Phase 3 trial of sequential versus combination treatment in colorectal cancer: The C-cubed study. *Eur J Cancer*. 2022;169:166-178. doi:10.1016/j.ejca.2022.04.009

Jones RP, Sutton PA, Evans JP, et al. Specific mutations in KRAS codon 12 are associated with worse overall survival in patients with advanced and recurrent colorectal cancer. *Br J Cancer*. 2017;116(7):923-929. doi:10.1038/bjc.2017.37

Kopetz S, Grothey A, Van Cutsem E, et al. Quality of life with encorafenib plus cetuximab with or without binimetinib treatment in patients with BRAF V600E-mutant metastatic colorectal cancer: patient-reported outcomes from BEACON CRC. *ESMO Open*. 2022;7(3):100477. doi:10.1016/j.esmoop.2022.100477

Le Rolle AF, Klempner SJ, Garrett CR, et al. Identification and characterization of *RET* fusions in advanced colorectal cancer. *Oncotarget*. 2015;6(30):28929-28937. doi:10.18632/oncotarget.4325

EXPERT PERSPECTIVES: THE NEXT ERA IN THE MANAGEMENT OF METASTATIC COLORECTAL CANCER

Lee GH, Malietzis G, Askari A, et al. Is right-sided colon cancer different to left-sided colorectal cancer? – a systematic review. *Eur J Surg Oncol*. 2015;41:300–308. doi:10.1016/j.ejso.2014.11.001

Lenz HJ, Overman MJ, Van Cutsem E, et al. First-line nivolumab + ipilimumab in patients with microsatellite instability–high/mismatch repair–deficient metastatic colorectal cancer: 64-month follow-up from CheckMate 142. *J Clin Oncol*. 2024;42(3 Suppl):97. doi:10.1200/JCO.2024.42.3_suppl.97

Lenz HJ, Van Cutsem E, Limon LM, et al. First-line nivolumab plus low-dose ipilimumab for microsatellite instability–high/mismatch repair–deficient metastatic colorectal cancer: The phase II CheckMate 142 study. *J Clin Oncol*. 2022;40(2):161-170. doi:10.1200/JCO.21.01015

Li J, Qin S, Xu RH, et al. Effect of fruquintinib vs placebo on overall survival in patients with previously treated metastatic colorectal cancer: The FRESKO randomized clinical trial. *JAMA*. 2018;319(24):2486-2496. doi:10.1001/jama.2018.7855

Mayer RJ, Cutsem EV, Falcone A, et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. *N Eng J Med*. 2015;372(20):1909-1919. doi:10.1056/NEJMoa1414325

Mosele F, Remon J, Mateo J, et al. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. *Ann Oncol*. 2020;31(11):1491-1505. doi:10.1016/j.annonc.2020.07.014

Mur P, Garcia-Mulero S, Del Valle J, et al. Role of POLE and POLD1 in familial cancer. *Genet Med*. 2020;22(12):2089-2100. doi:10.1038/s41436-020-0922-2

National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Colon Cancer. Version 3.2024. Accessed June 26, 2024.
<https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1428>

Neumann J, Zeindl-Eberhart E, Kirchner T, Jung A. Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer. *Pathol Res Pract*. 2009;205(12):858-862. doi:10.1016/j.prp.2009.07.010

Okamura R, Boichard A, Kato S, Sicklick JK, Bazhenova L, Kurzrock R. Analysis of *NTRK* alterations in pan-cancer adult and pediatric malignancies: Implications for *NTRK*-targeted therapeutics. *JCO Precis Oncol*. 2018;(2):1-20. doi:10.1200/po.18.00183

Parikh AR, Leshchiner I, Elagina L, et al. Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers. *Nat Med*. 2019;25(9):1415-1421. doi:10.1038/s41591-019-0561-9

Pfeiffer P, Yilmaz M, Moller S, et al. TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: An investigator-initiated, open-label, randomized, phase 2 trial. *Lancet Oncol*. 2020;21(3):412-420. doi:10.1016/S1470-2045(19)30827-7

EXPERT PERSPECTIVES: THE NEXT ERA IN THE MANAGEMENT OF METASTATIC COLORECTAL CANCER

Pietrantonio F, Petrelli F, Coinu A, et al. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis. *Eur J Cancer*. 2015;51(5):587-594. doi:10.1016/j.ejca.2015.01.054

Prager GW, Taieb J, Fakih M, et al. Trifluridine-tipiracil and bevacizumab in refractory metastatic colorectal cancer. *N Engl J Med*. 2023;338(18):1657-1667. doi:10.1056/NEJMoa2214963

Qiu MZ, Pan WT, Lin JZ, et al. Comparison of survival between right-sided and left-sided colon cancer in different situations. *Cancer Med*. 2018;7(4):1141–1150. doi:10.1002/cam4.1401

Raghav KPS, Siena S, Takashima A, et al. Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-overexpressing/amplified (HER2+) metastatic colorectal cancer (mCRC): primary results from the multicenter, randomized, phase 2 DESTINY-CRC02 study. *J Clin Oncol*. 2023;41(Suppl 16):3501. doi:10.1200/JCO.2023.41.16_suppl.3501

Rankin A, Klemptner SJ, Erlich R, et al. Broad detection of alterations predicted to confer lack of benefit from EGFR antibodies or sensitivity to targeted therapy in advanced colorectal cancer. *Oncologist*. 2016;21(11):1306-1314. doi:10.1634/theoncologist.2016-0148

Shiu K, André T, Kim TW, et al. Pembrolizumab versus chemotherapy in microsatellite instability–high/mismatch repair–deficient metastatic colorectal cancer: 5-year follow-up of the randomized phase III KEYNOTE-177 study. *Ann Oncol*. 2023;34(Suppl 2):S1254-S1335. doi: 10.1016/S0923-7534(23)04149-2

Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. *CA Cancer J Clin*. 2023;73(1):17-48. doi:10.3322/caac.21763

Subbiah V, Wolf J, Konda B, et al. Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial. *Lancet Oncol*. 2022;23(10):1261-1273. doi:10.1016/S1470-2045(22)00541-1

Tol J, Nagtegaal ID, Punt CJA. BRAF mutation in metastatic colorectal cancer. *N Engl J Med*. 2009;361(1):98-99. doi:10.1056/nejmc0904160

Valtorta E, Martino C, Sartore-Bianchi A, et al. Assessment of a HER2 scoring system for colorectal cancer: results from a validation study. *Mod Pathol*. 2015;28(11):1481-1491. doi:10.1038/modpathol.2015.98

Van Cutsem E, Köhne CH, Láng I, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: Updated analysis of overall survival according to tumor *KRAS* and *BRAF* mutation status. *J Clin Oncol*. 2011;29(15):2011-2019. doi:10.1200/jco.2010.33.5091

Venook AP, Niedzwiecki D, Lenz HJ, et al. Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with *KRAS* wild-type advanced or metastatic colorectal cancer: a randomized clinical trial. *JAMA*. 2017;317(23):2392-2401. doi:10.1001/jama.2017.7105

EXPERT PERSPECTIVES: THE NEXT ERA IN THE MANAGEMENT OF METASTATIC COLORECTAL CANCER

Wang F, Zhao Q, Wang YN, et al. Evaluation of POLE and POLD1 mutations as biomarkers for immunotherapy outcomes across multiple cancer types. *JAMA Oncol.* 2019;5(10):1504. doi:10.1001/jamaoncol.2019.2963

Xie YH, Chen YX, Fang JY. Comprehensive review of targeted therapy for colorectal cancer. *Signal Transduct Target Ther.* 2020;5(1):22. doi:10.1038/s41392-020-0116-z